Compare Biogen Inc (BIIB) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Visa Inc — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Visa Inc trades at $361 (market cap $671.74B). The key difference: Visa Inc is far larger — about 22.3× Biogen Inc's market cap, and Visa Inc pays a 0.74% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | V | |
|---|---|---|
Market Cap | $30.13B | $671.74B |
Sector | Health | Financials |
52-Week High | $216.63 | $370.47 |
52-Week Low | $128.93 | $295.52 |
Enterprise Value | $37.20B | $682.32B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $3.32 exceeding the $3.23 estimate. Revenue grew to $40 billion in 2025, with a net income margin of 50.78%. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.
The outlook remains positive due to high analyst buy ratings (85.48%) and a consensus price target of $426.31, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and profitability support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
